Amyloidosis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Amyloidosis - Pipeline Review, H1 2019’, provides an overview of the Amyloidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Amyloidosis

- The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects

- The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Amyloidosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Amyloidosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Bsim2

Celgene Corp

Chugai Pharmaceutical Co Ltd

Eidos Therapeutics Inc

Johnson & Johnson

Neurimmune Holding AG

Oncopeptides ...

Akcea Therapeutics Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Bsim2

Celgene Corp

Chugai Pharmaceutical Co Ltd

Eidos Therapeutics Inc

Johnson & Johnson

Neurimmune Holding AG

Oncopeptides AB

Pfizer Inc

Prothena Corp Plc

R Pharm

Regeneron Pharmaceuticals Inc

Spectrum Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents

Introduction

Amyloidosis - Overview

Amyloidosis - Therapeutics Development

Amyloidosis - Therapeutics Assessment

Amyloidosis - Companies Involved in Therapeutics Development

Amyloidosis - Drug Profiles

Amyloidosis ...

Table of Contents

Table of Contents

Introduction

Amyloidosis - Overview

Amyloidosis - Therapeutics Development

Amyloidosis - Therapeutics Assessment

Amyloidosis - Companies Involved in Therapeutics Development

Amyloidosis - Drug Profiles

Amyloidosis - Dormant Projects

Amyloidosis - Discontinued Products

Amyloidosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Amyloidosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Tables

Number of Products under Development for Amyloidosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Amyloidosis - Pipeline by Akcea Therapeutics Inc, H1 2019

Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H1 2019

Amyloidosis - Pipeline by Amgen Inc, H1 2019

Amyloidosis - Pipeline by Bsim2, H1 2019

Amyloidosis - Pipeline by Celgene Corp, H1 2019

Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2019

Amyloidosis - Pipeline by Eidos Therapeutics Inc, H1 2019

Amyloidosis - Pipeline by Johnson & Johnson, H1 2019

Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2019

Amyloidosis - Pipeline by Oncopeptides AB, H1 2019

Amyloidosis - Pipeline by Pfizer Inc, H1 2019

Amyloidosis - Pipeline by Prothena Corp Plc, H1 2019

Amyloidosis - Pipeline by R Pharm, H1 2019

Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2019

Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H1 2019

Amyloidosis - Dormant Projects, H1 2019

Amyloidosis - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Amyloidosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under ...

List of Figures

Number of Products under Development for Amyloidosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports